These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16166436)

  • 1. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.
    Brait M; Banerjee M; Maldonado L; Ooki A; Loyo M; Guida E; Izumchenko E; Mangold L; Humphreys E; Rosenbaum E; Partin A; Sidransky D; Hoque MO
    Oncotarget; 2017 Feb; 8(9):15431-15440. PubMed ID: 28147335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
    Abramovic I; Pezelj I; Dumbovic L; Skara Abramovic L; Vodopic T; Bulimbasic S; Stimac G; Bulic-Jakus F; Kulis T; Katusic Bojanac A; Tomas D; Ulamec M; Sincic N
    Prostate; 2024 Sep; 84(12):1128-1137. PubMed ID: 38824441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
    Henrique R; Oliveira AI; Costa VL; Baptista T; Martins AT; Morais A; Oliveira J; Jerónimo C
    BMC Genomics; 2013 Dec; 14():898. PubMed ID: 24344919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
    Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.
    Maldonado L; Brait M; Loyo M; Sullenberger L; Wang K; Peskoe SB; Rosenbaum E; Howard R; Toubaji A; Albadine R; Netto GJ; Hoque MO; Platz EA; Sidransky D
    J Urol; 2014 Nov; 192(5):1542-8. PubMed ID: 24769028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
    Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
    PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.
    Pugongchai A; Bychkov A; Sampatanukul P
    Int J Exp Pathol; 2017 Dec; 98(6):341-346. PubMed ID: 29315911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.
    Xie GS; Li G; Li Y; Pu JX; Huang YH; Li JH; Yin HM
    Chin Med J (Engl); 2019 Nov; 132(22):2684-2689. PubMed ID: 31725446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients.
    Aykanli E; Arisan S; Arisan ED; Yavuzsan AH
    Urol J; 2024 May; 21(3):182-188. PubMed ID: 38493315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.
    Kirby MK; Ramaker RC; Roberts BS; Lasseigne BN; Gunther DS; Burwell TC; Davis NS; Gulzar ZG; Absher DM; Cooper SJ; Brooks JD; Myers RM
    BMC Cancer; 2017 Apr; 17(1):273. PubMed ID: 28412973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the Diagnosis of Prostate Cancer with a Novel Blood-Based Biomarker: Comparison of Its Performance with Prostate-Specific Antigen.
    Sanders JL; Iczkowski KA; Shah GV
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.
    Chen Y; Li J; Yu X; Li S; Zhang X; Mo Z; Hu Y
    Eur J Hum Genet; 2013 Sep; 21(9):929-35. PubMed ID: 23299921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of serum tumor abnormal protein in prostate cancer patients.
    Fu L; Zhang C; Wang Z; Tao W; Zhu J; Zhou Y; Sun C; Xue B; Yu M; Xu L; Zang Y
    BMC Cancer; 2024 May; 24(1):665. PubMed ID: 38822321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Mavridis K; Avgeris M; Koutalellis G; Stravodimos K; Scorilas A
    Cancer Sci; 2010 Mar; 101(3):693-9. PubMed ID: 20067463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer.
    Amoako YA; Hammond ENB; Assasie-Gyimah A; Laryea DO; Ankrah A; Amoah G
    World J Nucl Med; 2019; 18(2):143-148. PubMed ID: 31040745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer.
    Ke Z; Xu Y; Shu Y; Wang C; Wu B; Zhang B; Xiang P; Hu X
    Transl Cancer Res; 2024 Feb; 13(2):676-685. PubMed ID: 38482405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.
    Ahmad AS; Vasiljević N; Carter P; Berney DM; Møller H; Foster CS; Cuzick J; Lorincz AT
    Oncotarget; 2016 Nov; 7(44):71833-71840. PubMed ID: 27708246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen.
    Zheng SL; Sun J; Wiklund F; Gao Z; Stattin P; Purcell LD; Adami HO; Hsu FC; Zhu Y; Adolfsson J; Johansson JE; Turner AR; Adams TS; Liu W; Duggan D; Carpten JD; Chang BL; Isaacs WB; Xu J; Grönberg H
    Clin Cancer Res; 2009 Feb; 15(3):1105-11. PubMed ID: 19188186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation gene-based models indicating independent poor outcome in prostate cancer.
    Vasiljević N; Ahmad AS; Thorat MA; Fisher G; Berney DM; Møller H; Foster CS; Cuzick J; Lorincz AT
    BMC Cancer; 2014 Sep; 14():655. PubMed ID: 25193387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.